Initial Discovery

RLBN1001: A highly active drug prototype

A prototype drug (RLBN1001) was tested in more than 370 patients for non-metabolic uses over a 10-year period. Relburn investigators first observed that this drug very rapidly reduced serum uric acid to an extremely low level.
 
With this clinical proof-of-concept, Relburn pursued this lead by identifying each of the underlying biologic mechanisms that produced this unusually potent activity. Relburn then synthesized a library of novel derivative compounds that enhanced these activities and also reduced risks of potential side-effects.
From this library, The Company intends to take two discrete patented drugs into clinical development as treatment for chronic inflammatory diseases, specifically NASH and gout.